Trinity Biotech, the Wicklow-based manufacturer of diagnostic products, will acquire the assets and goodwill of the Biopool Hemostasis division of Xtrana Inc.
It will pay $6.25 million (€7 million) for the assets of the US-based company, comprising an up-front cash payment of $3.6 million and the balance due in deferred payments over a 36-month period.
The transaction includes the purchase of fixed assets, inventory and debtors, and will add to Trinity's earnings in 2002.
Completion of the sale is subject to the approval of a majority of Xtrana's stockholders at a special meeting scheduled for December.
Founded in 1982, Biopool develops, manufactures and markets a full range of test kits to assess and diagnose disorders of blood coagulation, thrombotic risk factors, fibrinolysis, platelet function and the vascular system.
Trinity Biotech develops, manufactures and markets more than 200 diagnostic products for the point-of-care, self-testing and clinical laboratory segments of the diagnostic market.
